
Wolves' reintroduction to Highlands could help native woodlands to recover, says study
Reintroducing wolves in the Scottish Highlands could lead to an expansion of native woodland which could take in and store 1m tonnes of carbon dioxide a year, researchers have suggested.
A study led by researchers at the University of Leeds said that reintroducing the species into the Cairngorms, as well as the south-west, north-west and central Highlands could help curb the problem of red deer eating tree saplings, which stops natural woodland regeneration.
The scientists estimated that if wolves were reintroduced, a population of about 167 of the animals would thrive, which they said is enough to reduce red deer populations to a level that would allow trees to regenerate naturally.
The research suggested this alone could contribute to about 5% of the carbon removal target for UK woodlands, roughly equivalent to 1m tonnes.
The study estimated that each wolf would lead to an annual carbon uptake capability of 6,080 tonnes of CO2, making each wolf worth about £154,000, using accepted valuations of carbon.
The research, which was published on Monday in the Ecological Solutions and Evidence journal, is the first time that the impact of reintroducing wolves would have on woodland expansion and carbon storage in the UK has been recorded.
The study's lead author, Prof Dominick Spracklen, from the university's school of earth and environment, said: 'There is an increasing acknowledgment that the climate and biodiversity crises cannot be managed in isolation.
'We need to look at the potential role of natural processes such as the reintroduction of species to recover our degraded ecosystems and these in turn can deliver co-benefits for climate and nature recovery.'
It is widely accepted that wolves were officially eradicated from Scotland about 250 years ago, though the exact year is not known. This left red deer with no natural predators, and while efforts have been made to keep the population under control, it has increased over the last 100 years to an estimated 400,000 today in Scotland alone.
The researchers said only 4% of Scotland is covered by woodland today, making it one of the least forested places in Europe.
The wolf population in western Europe is about 12,000, and the animals occupy 67% of their former territory.
The researchers have said they expect some backlash to their research, particularly from farmers concerned about livestock and deer stalkers.
Sign up to Down to Earth
The planet's most important stories. Get all the week's environment news - the good, the bad and the essential
after newsletter promotion
The policy of reintroducing wolves as apex predators in Scotland has been intensely divisive, with some farmers and rural communities opposed to the measure. Wolf populations have also been lightning rods for discussion in Europe, where the species has had a remarkable comeback.
But the researchers say the benefits must be considered.
Lee Schofield, a co-author of the study, said: 'Our aim is to provide new information to inform ongoing and future discussions about the possibility of wolf reintroductions both in the UK and elsewhere.
'We recognise that substantial and wide-ranging stakeholder and public engagement would clearly be essential before any wolf reintroduction could be considered.
'Human-wildlife conflicts involving carnivores are common and must be addressed through public policies that account for people's attitudes for a reintroduction to be successful.'
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Medical News Today
04-06-2025
- Medical News Today
Colon cancer: Exercise as important as drugs in preventing recurrence
Could exercise be 'better than a drug' at preventing colon cancer recurrence? Image credit: Connect Images/. Colorectal cancer is the third most common cancer worldwide, and the second leading cause of cancer deaths. Treatments include surgery, radiotherapy and chemotherapy. After initial treatment, people are advised to follow a healthy lifestyle, often in conjunction with further drug treatments to try and reduce the chance of recurrence. Now, a study has found that a structured exercise program could be more effective than drug treatments in preventing colon cancer recurrence. Patients following a supervised exercise program had a 28% lower risk of recurrence, and a 37% lower risk of death from any cause than those who were not. Now, a study led by Canadian scientists has found that a structured exercise program following surgery and chemotherapy for colon cancer reduced patients' chance of cancer recurring by 28% compared with patients given only health advice. Experts have said these results suggest exercise could be 'better than a drug' at preventing colon cancer recurrence. Speaking to the Science Media Centre, David Sebag-Montefiore, MB BS, MRCP, FRCP, the Audrey and Stanley Burton Professor of Clinical Oncology and Health Research, University of Leeds, United Kingdom, who was not involved in the trial, commented that: 'This is excellent news for future patients with bowel cancer and is likely to bring additional health benefits […[ The great appeal of a structured moderate intensity exercise is that is offers the benefits without the downside of the well-known side effects of our other treatments.' All those enrolled in the trial, between 2009 and 2024, had undergone surgery for stage 3 or high-risk stage 2 colon cancer, followed by adjuvant chemotherapy to help prevent the cancer returning. They ranged in age from 19 to 84 years, with a median age of 61. Most participants had a body mass index (BMI) indicating overweight or obesity, and none exercised for more than 150 minutes per week before the trial. Researchers randomly assigned all participants to one of two groups. The exercise group — made up of 445 patients — worked with a certified physical activity consultant for 3 years. For the first 6 months the consultants saw them every week, then fortnightly for the second 6 months, and monthly for next 2 years. These participants could choose the type, frequency and intensity of aerobic exercise, but the aim was to achieve the equivalent of 3-4 brisk 45-60 minute walks a week. The health-education group (444 patients) received general health-education materials promoting physical activity and healthy nutrition in addition to standard surveillance. At a median follow-up of 7.9 years, 93 people in the exercise group and 131 in the health-education group had experienced a recurrence of their cancer, a new primary cancer, or had died. In total, 107 died from any cause — 41 in the exercise group, 66 in the health-education group. People in the exercise group did not lose weight, but saw a general improvement in physical functioning and significantly longer disease-free survival, with an annual incidence of recurrence, new primary cancer, or death of 3.7%, compared with 5.4% in the health-education group. In the exercise group, 80.3% of patients were disease-free after 5 years, compared with 73.9% of the health-education group. Lead author on the study, Kerry S. Courneya, PhD, Professor and Canada Research Chair in Physical Activity and Cancer at the University of Alberta in Edmonton, Canada, told Medical News Today that the most important finding of their study was the overall improvement in survival. Julie Gralow, MD, Chief Medical Officer of the American Society of Clinical Oncology (ASCO), who was not involved in the trial, said the findings suggest that exercise could be 'better than a drug' for cancer patient outcomes, because it does not have the related side effects. However, she cautioned: 'I did not mean to suggest that we omit drugs in favor of exercise, my intention was to compare the magnitude of benefit we get from standard therapies to what exercise achieved in terms of reduction of recurrences and deaths, also taking toxicity into account.' She added that while there were effective drugs that help prevent recurrence in patients with particular mutations for colon cancer, 'exercise's benefit in colon cancer patients is not restricted to these specific mutations.' Courneya emphasized the benefits of their program: 'The 'side effects' of exercise are almost all good (fitter, stronger, less fatigue, less depression, lower [cardiovascular disease] risk, etc.). I think exercise keeps having an effect on new primary cancers and possibly other causes of death. Intervention participants were still doing more exercise than health education at years 4 and 5.' A supervised exercise program can also be much cheaper than medication. 'The [physical activity] intervention was maybe 3,000 to 5,000 [Canadian dollars] whereas it is not uncommon for some cancer drugs to be 10s of thousands and even reach 100,000,' Courneya added. Vicky Coyle, U.K. lead researcher for the trial and Clinical Professor at Queen's University Belfast, Northern Ireland, told MNT that: 'Our study gives clear, encouraging evidence that physical activity can reduce the risk of cancer returning for some people with colon cancer. We now need to work with policymakers and healthcare providers to embed exercise into treatment plans where appropriate.' Joe Henson, PhD, Associate Professor in Lifestyle Medicine at the University of Leicester, who led exercise sessions in Leicester, U.K. for the trial, highlighted the need for support. 'Despite its proven benefits, many people still face barriers to engaging in regular exercise. This study shows how important it is to make exercise advice a routine part of cancer care and to offer people tailored support,' Henson told us. Although she emphasizes the importance of exercise to her own patients, Gralow noted that implementing exercise programs like those in this study could be difficult: 'I question whether most clinics have enough personnel to accommodate this number of visits (especially since prior observational data suggests many other cancer types — including common ones like breast and prostate cancer — benefit from exercise). I also question whether all or even most patients are willing to come in this often.' 'So,' she said, 'we need to find alternative ways to support our patients in incorporating exercise into their lives that do not require clinic visits but do provide regular support and encouragement. And we need to make sure we, the clinicians, are recommending this (a prescription for exercise!).' Colorectal Cancer Cancer / Oncology Sports Medicine / Fitness


Scottish Sun
03-06-2025
- Scottish Sun
The cheap 90p supplement that could slash risk of deadly heart failure by ‘reversing' damage from silent killer
Click to share on X/Twitter (Opens in new window) Click to share on Facebook (Opens in new window) A CHEAP supplement could help prevent deadly heart failure by 'reversing' damage caused by silent killer diabetes. People with type 2 diabetes who took the widely available pill daily on top of their standard treatment were able to reverse early signs of diabetes-related heart failure in a matter of months, a new study showed. Sign up for Scottish Sun newsletter Sign up 1 Mitoquinone supplements could help protect the hearts of people with type 2 diabetes Credit: Getty The number Brits with diabetes has reached an all-time high - it's estimated that 5.8 million people have the condition, 90 per cent of whom have type 2 diabetes. This number is predicted to continue surging. Type 2 diabetes patients are up to five times more likely to develop heart failure than the rest of the population, according to the British Heart Foundation (BHF). Once someone with diabetes is diagnosed with heart failure, they are three times more likely to die over the next five years. But a study conducted by the University of Leeds found that diabetics who took mitoquinone - sold as a health supplement for about 90p per tablet - had healthier hearts after four months compared to those not given the supplement. Lead author Dr Henry Procter, a clinical research fellow at the University of Leeds, said: 'These encouraging results are a sign that mitoquinone could keep hearts healthier for longer in people with diabetes. "If the study had continued for longer, it is likely we would have started to see differences in more serious indicators of heart health between the group with mitoquinone and the group without.' Diabetes causes problems with how the body - including the heart - processes and uses energy, which can cause stress and damage to the cells of the heart muscle. Over time, it can lead to the heart stiffening and being unable to pump blood well, eventually to the point of heart failure. Mitoquinone is an artificial antioxidant that is thought to guard cells against this metabolic stress and damage. High blood pressure, high cholesterol and type 2 diabetes are all dubbed 'silent killers' - should we really be that worried? It's sold online as a supplement for about £50 for a jar of 60 pills, which works out at about 86p per tablet. However, these are at doses far lower than those used in the study. The research, whose results were presented at the British Cardiovascular Society conference in Manchester, involved 70 patients with type 2 diabetes who didn't have heart failure. Half were given 40mg of mitoquinone per day on top of their regular diabetes treatment, while the other half received their usual medication. Both groups had their heart health assessed at the start of the study and again four months later. After four months of mitoquinone, diabetic patients' hearts were able to process and use energy 15 per cent more efficiently. Their heart muscles were also able to relax more quickly, which showed that early indicators of stress and stiffness in their hearts had been reversed, according to researchers. Patients experienced no side effects from taking the supplement. What is heart failure and tips to prevent it Heart failure is a condition where your heart can't pump blood around your body as well as it should. It doesn't mean your heart has stopped working but you may need support to help it work better. When your heart isn't pumping blood as well as it should, it means you're not getting enough oxygen. This affects how your body works, including your breathing and muscles. This causes some of the main symptoms of heart failure, like: Fainting or feeling lightheaded Feeling increasingly tired or weak at rest which gets worse with movement New persistent cough Shortness of breath when you're active or resting Swelling in your feet and ankles which can spread to your lower body You should see your GP as soon as you can if you experience any of these symptoms. To manage heart failure, here are some things you could try: Keeping active – which has been proven to boost energy and improve sleep and quality of life. Keeping to a healthy weight and diet – this will help your overall health and prevent extra strain on your heart. Limiting how much alcohol you drink (less than the recommended 14 units per week) - lowering your chance of getting abnormal heart rhythms, high blood pressure and diseases such as stroke, liver problems and some cancers. Stopping smoking and using other tobacco products - reducing your risk of developing heart and circulatory diseases. Watching the amount of fluid you have each day if advised by your medical team. Weighing yourself regularly – sudden weight gain may mean too much fluid is building up in your body and will need treated. Source: BHF Those who didn't take the daily pill didn't see the same improvements to their heart health. Experts said that while their findings are promising they now need to be backed up by larger trials. The research team is now looking into running a larger study of mitoquinone in diabetes patients, to gather more evidence that the supplement could protect their hearts and prevent heart failure over time. They hope to show that diabetes patients could one day be prescribed mitoquinone to keep their hearts healthier for longer. 'We hope that a larger study will continue to demonstrate the benefits of this antioxidant, and that one day soon diabetic patients can be prescribed it to help prevent heart failure before it ever affects their lives," Dr Procter said. Professor Bryan Willians, the BHF's chief scientific and medical officer, added: 'This study presents some intriguing initial findings. "It's still early days for this research and the results will need to be confirmed in a larger scale trial. "The study neatly demonstrates why it is so important to continue to support research and look for solutions in a wide variety of places, so that we can continue to offer hope to people living with, and at risk of, cardiovascular disease.'


The Sun
03-06-2025
- The Sun
The cheap 90p supplement that could slash risk of deadly heart failure by ‘reversing' damage from silent killer
A CHEAP supplement could help prevent deadly heart failure by 'reversing' damage caused by silent killer diabetes. People with type 2 diabetes who took the widely available pill daily on top of their standard treatment were able to reverse early signs of diabetes-related heart failure in a matter of months, a new study showed. 1 The number Brits with diabetes has reached an all-time high - it's estimated that 5.8 million people have the condition, 90 per cent of whom have type 2 diabetes. This number is predicted to continue surging. Type 2 diabetes patients are up to five times more likely to develop heart failure than the rest of the population, according to the British Heart Foundation (BHF). Once someone with diabetes is diagnosed with heart failure, they are three times more likely to die over the next five years. But a study conducted by the University of Leeds found that diabetics who took mitoquinone - sold as a health supplement for about 90p per tablet - had healthier hearts after four months compared to those not given the supplement. Lead author Dr Henry Procter, a clinical research fellow at the University of Leeds, said: 'These encouraging results are a sign that mitoquinone could keep hearts healthier for longer in people with diabetes. "If the study had continued for longer, it is likely we would have started to see differences in more serious indicators of heart health between the group with mitoquinone and the group without.' Diabetes causes problems with how the body - including the heart - processes and uses energy, which can cause stress and damage to the cells of the heart muscle. Over time, it can lead to the heart stiffening and being unable to pump blood well, eventually to the point of heart failure. Mitoquinone is an artificial antioxidant that is thought to guard cells against this metabolic stress and damage. It's sold online as a supplement for about £50 for a jar of 60 pills, which works out at about 86p per tablet. However, these are at doses far lower than those used in the study. The research, whose results were presented at the British Cardiovascular Society conference in Manchester, involved 70 patients with type 2 diabetes who didn't have heart failure. Half were given 40mg of mitoquinone per day on top of their regular diabetes treatment, while the other half received their usual medication. Both groups had their heart health assessed at the start of the study and again four months later. After four months of mitoquinone, diabetic patients' hearts were able to process and use energy 15 per cent more efficiently. Their heart muscles were also able to relax more quickly, which showed that early indicators of stress and stiffness in their hearts had been reversed, according to researchers. Patients experienced no side effects from taking the supplement. What is heart failure and tips to prevent it Heart failure is a condition where your heart can't pump blood around your body as well as it should. It doesn't mean your heart has stopped working but you may need support to help it work better. When your heart isn't pumping blood as well as it should, it means you're not getting enough oxygen. This affects how your body works, including your breathing and muscles. This causes some of the main symptoms of heart failure, like: Fainting or feeling lightheaded Feeling increasingly tired or weak at rest which gets worse with movement New persistent cough Shortness of breath when you're active or resting Swelling in your feet and ankles which can spread to your lower body You should see your GP as soon as you can if you experience any of these symptoms. To manage heart failure, here are some things you could try: Keeping active – which has been proven to boost energy and improve sleep and quality of life. Keeping to a healthy weight and diet – this will help your overall health and prevent extra strain on your heart. Limiting how much alcohol you drink (less than the recommended 14 units per week) - lowering your chance of getting abnormal heart rhythms, high blood pressure and diseases such as stroke, liver problems and some cancers. Stopping smoking and using other tobacco products - reducing your risk of developing heart and circulatory diseases. Watching the amount of fluid you have each day if advised by your medical team. Weighing yourself regularly – sudden weight gain may mean too much fluid is building up in your body and will need treated. Source: BHF Those who didn't take the daily pill didn't see the same improvements to their heart health. Experts said that while their findings are promising they now need to be backed up by larger trials. The research team is now looking into running a larger study of mitoquinone in diabetes patients, to gather more evidence that the supplement could protect their hearts and prevent heart failure over time. They hope to show that diabetes patients could one day be prescribed mitoquinone to keep their hearts healthier for longer. 'We hope that a larger study will continue to demonstrate the benefits of this antioxidant, and that one day soon diabetic patients can be prescribed it to help prevent heart failure before it ever affects their lives," Dr Procter said. Professor Bryan Willians, the BHF's chief scientific and medical officer, added: 'This study presents some intriguing initial findings. "It's still early days for this research and the results will need to be confirmed in a larger scale trial. "The study neatly demonstrates why it is so important to continue to support research and look for solutions in a wide variety of places, so that we can continue to offer hope to people living with, and at risk of, cardiovascular disease.'